Sinopep-Allsino Biopharmaceutical Co. Ltd. A Market Cap ($1.28 Billion)
Market Cap & Net Worth: Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076)
Sinopep-Allsino Biopharmaceutical Co. Ltd. A market cap. Sinopep-Allsino Biopharmaceutical Co. Ltd. A (SHG:688076) has a market capitalization of $1.28 Billion (CN¥8.73 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #7616 globally and #1649 in its home market, demonstrating a 1.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sinopep-Allsino Biopharmaceutical Co. Ltd. A's stock price CN¥27.54 by its total outstanding shares 316815961 (316.82 Million). Also see cash efficiency ratio of Sinopep-Allsino Biopharmaceutical Co. Lt for how efficiently the company converts equity into cash flow.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Market Cap History (2021–2026)
Sinopep-Allsino Biopharmaceutical Co. Ltd. A market cap history from 2021 to 2026. Data shows change from $1.88 Billion to $1.28 Billion (-16.94% CAGR). Check Sinopep-Allsino Biopharmaceutical Co. Lt share price for real-time trading data and today's change.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Sinopep-Allsino Biopharmaceutical Co. Lt (688076) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.90x
Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market cap is 0.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.34x
Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market cap is 5.34 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.88 Billion | $643.87 Million | $115.39 Million | 2.92x | 16.29x |
| 2022 | $1.05 Billion | $651.29 Million | $129.11 Million | 1.61x | 8.13x |
| 2023 | $2.07 Billion | $1.03 Billion | $162.94 Million | 2.00x | 12.68x |
| 2024 | $2.41 Billion | $1.62 Billion | $404.39 Million | 1.48x | 5.95x |
| 2025 | $1.75 Billion | $1.94 Billion | $327.00 Million | 0.90x | 5.34x |
Competitor Companies of 688076 by Market Capitalization
Companies near Sinopep-Allsino Biopharmaceutical Co. Ltd. A in the global market cap rankings as of November 8, 2026. Also see 688076 current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Sinopep-Allsino Biopharmaceutical Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2021–2026)
Market capitalization of Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2021 to today. Between 2021 and today, Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market cap moved from $1.88 Billion to $ 1.28 Billion, with a yearly change of -16.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.28 Billion | -26.95% |
| 2025 | CN¥1.75 Billion | -27.39% |
| 2024 | CN¥2.41 Billion | +16.47% |
| 2023 | CN¥2.07 Billion | +97.02% |
| 2022 | CN¥1.05 Billion | -44.18% |
| 2021 | CN¥1.88 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Sinopep-Allsino Biopharmaceutical Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.28 Billion USD |
| MoneyControl | $1.28 Billion USD |
| MarketWatch | $1.28 Billion USD |
| marketcap.company | $1.28 Billion USD |
| Reuters | $1.28 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sinopep-Allsino Biopharmaceutical Co. Ltd. A
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was… Read more